著者

Hitoshi Ogino Osamu Iida Koichi Akutsu Yoshiro Chiba Hiromitsu Hayashi Hatsue Ishibashi-Ueda Shuichiro Kaji Masaaki Kato Kimihiro Komori Hitoshi Matsuda Kenji Minatoya Hiroko Morisaki Takao Ohki Yoshikatsu Saiki Kunihiro Shigematsu Norihiko Shiiya Hideyuki Shimizu Nobuyoshi Azuma Hirooki Higami Shigeo Ichihashi Toru Iwahashi Kentaro Kamiya Takahiro Katsumata Nobuyoshi Kawaharada Yoshihisa Kinoshita Takuya Matsumoto Shinji Miyamoto Takayuki Morisaki Tetsuro Morota Kiyonori Nanto Toshiya Nishibe Kenji Okada Kazumasa Orihashi Junichi Tazaki Masanao Toma Takuro Tsukube Keiji Uchida Tatsuo Ueda Akihiko Usui Kazuo Yamanaka Haruo Yamauchi Kunihiro Yoshioka Takeshi Kimura Tetsuro Miyata Yutaka Okita Minoru Ono Yuichi Ueda on behalf of the Japanese Circulation Society the Japanese Society for Cardiovascular Surgery the Japanese Association for Thoracic Surgery and the Japanese Society for Vascular Surgery Joint Working Group

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

pp.CJ-22-0794, (Released:2023-09-01)

参考文献数

1943

被引用文献数

10

著者

Michinao Tan Mitsuyoshi Takahara Takuya Haraguchi Daiki Uchida Yutaka Dannoura Tsuyoshi Shibata Shuko Iwata Nobuyoshi Azuma

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

pp.CJ-23-0348, (Released:2023-08-04)

参考文献数

21

被引用文献数

2

---

Background: Acute limb ischemia (ALI) is a limb- and life-threatening condition and urgent treatment including revascularization should be offered to patients unless the limb is irreversibly ischemic. The aim of this study was to investigate 1-year clinical outcomes and prognostic factors following revascularization in patients with ALI.Methods and Results: A retrospective, multicenter, nonrandomized study examined 185 consecutive patients with ALI treated by surgical revascularization (SR), endovascular revascularization (ER), or hybrid revascularization (HR) in 6 Japanese medical centers from January 2015 to August 2021. The 1-year amputation-free survival (AFS) rate was estimated to be 69.2% (95% confidence interval [CI], 62.8–76.2%). There were no significant differences among SR, ER, and HR regarding both technical success and perioperative complications. Multivariate analysis revealed that Rutherford category IIb and III ischemia (hazard ratio [HR]: 1.86; 95% CI: 1.06–3.25), supra- to infrapopliteal lesion (HR: 2.06; 95% CI: 1.08–3.95), and technical failure (HR: 2.58; 95% CI: 1.49–4.46) were independent risk factors for 1-year AFS.Conclusions: Rutherford category IIb and III ischemia, supra- to infrapopliteal lesions, and technical failures were identified as independent risk factors for 1-year AFS. Furthermore, patients with multiple risk factors had a lower AFS rate.

著者

Keisuke Miyake Nobuyoshi Azuma Chugo Rinoie Shusaku Maeda Akima Harada Liu Li Itsunari Minami Shigeru Miyagawa Yoshiki Sawa

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

pp.CJ-22-0257, (Released:2022-09-27)

参考文献数

46

被引用文献数

2

---

Background: Although regenerative cell therapy is expected to be an alternative treatment for peripheral artery disease (PAD), many regenerative cell therapies have failed to show sufficient efficacy in clinical trials. Most preclinical studies have used acute ischemia models, despite PAD being a chronic disease. In addition, aging and atherosclerosis decrease the quality of a patient’s stem cells. Therefore, using a non-acute ischemic preclinical model and stem cells with high regenerative potency are important for the development of effective regenerative therapy. In this study, we assessed the tissue regenerative potential of umbilical cord-derived mesenchymal stromal cells (UCMSCs), which could potentially be an ideal cell source, in a rat model of established ischemia.Methods and Results: The regenerative capacity of UCMSCs was analyzed in terms of angiogenesis and muscle regeneration. In vitro analysis showed that UCMSCs secrete high amounts of cytokines associated with angiogenesis and muscle regeneration. In vivo experiments in a rat non-acute ischemia model showed significant improvement in blood perfusion after intravenous injection of UCMSCs compared with injection of culture medium or saline. Histological analysis revealed UCMSCs injection enhanced angiogenesis, with an increased number of von Willebrand factor-positive microcapillaries, and improved muscle regeneration.Conclusions: These results suggest that intravenous administration of UCMSCs may be useful for treating patients with PAD.